Luna Diabetes launched a pivotal trial for Luna, its miniature automated insulin delivery system. The company describes the system — designed to transform nighttime glucose management — as the world’s smallest patch pump. Luna delivers micro-doses of insulin while the user sleeps. According to the company, it offers the “simplest onboarding experience” of any automated insulin delivery system. It also has the first algorithm designed for use with insulin pens, the company’s co-founder John Sjölund said in a blog post.
Related: Sonavex raises $15M to support novel ultrasound solutions
“We’re thrilled to announce the launch of our pivotal trial for Luna, our innovative automated insulin delivery system designed to transform nighttime glucose management,” the company wrote in a LinkedIn post. “This is a crucial step in our journey to provide safer, more effective solutions for those needing insulin therapy.
Sjölund founded Luna alongside Jon Brilliant, who co-founded Bigfoot Biomedical (acquired by Abbott), and Sean Saint, Beta Bionics CEO. Sjölund, himself Luna’s CEO, co-founded and led Timesulin as CEO until its acquisition by Bigfoot Biomedical. After that, he served as VP of connected injection systems, then chief of staff at Bigfoot. He said managing diabetes became a part of his everyday life when diagnosed with type 1 diabetes at age 4. Sjölund now says Luna was born “out of necessity” for the difficulties of nighttime glucose management.
